Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury

Journal of Heart and Lung Transplantation

Volumn 18, Issue 9, 1999, Pages 862-868

  Stammberger, Uz ^a   Carboni, Giovanni L ^a   Hillinger, Sven ^a   Schneiter, Dieter ^a   Weder, Walter ^a   Schmid, Ralph A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; ENDOTHELIN RECEPTOR ANTAGONIST; MYELOPEROXIDASE; TAK 044; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GAS ANALYSIS; CONTROLLED STUDY; ISCHEMIA; LUNG TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; DRUG THERAPY, COMBINATION; ISOQUINOLINES; LIPID PEROXIDATION; LUNG; LUNG TRANSPLANTATION; MALE; OXYGEN; PEPTIDES, CYCLIC; PEROXIDASE; PLATELET ACTIVATING FACTOR; PYRIDINIUM COMPOUNDS; RATS; RATS, INBRED F344; RECEPTORS, ENDOTHELIN; REPERFUSION INJURY; TETRAHYDROISOQUINOLINES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0032837166     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00039-X     Document Type: Article

References (42)

1. Corcoran P.C., Tse S.S., Katz N.M., et al. Reduction of conjugated dienes in lung transplantation Effect of BN 52021 . Ann Thorac Surg. 56:1993;1279-1283.
2. Ide S., Kawahara K., Takahashi T., et al. Donor administration of PAF antagonist (TCV-309) enhances lung preservation. Transplant Proc. 27:1995;570-573.
3. Wahlers T., Hirt S.W., Haverich A., et al. Future horizons of lung preservation by application of a platelet-activating factor antagonist compared with current clinical standards. Euro-Collins flush perfusion vs donor core cooling. J Thorac Cardiovasc Surg. 103:1992;200-204.
4. Mizutani H., Minamoto K., Aoe M., et al. Expression of endothelin-1 and effects of an endothelin receptor antagonist, TAK-044, at reperfusion after cold preservation in a canine lung transplantation model. J Heart Lung Transplant. 17:1998;835-845.
5. Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I). Drugs. 42:1991;9-29.
6. Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. PAF. A review of its effects, antagonists and possible future clinical implications (Part II). Drugs. 42:1991;174-204.
7. Fink A., Geva D., Zung A., et al. Adult respiratory distress syndrome Roles of leukotriene C4 and platelet activating factor . Crit Care Med. 18:1990;905-910.
8. Sandoval D., Gukovskaya A., Reavey P., et al. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology. 111:1996;1081-1091.
9. Nassif A., Longo W.E., Mazuski J.E., Vernava A.M., Kaminski D.L. Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Dis Colon Rectum. 39:1996;217-223.
10. Ortiz A., Gomez C.M., Lerma J.L., Gonzalez E., Egido J. The role of platelet-activating factor (PAF) in experimental glomerular injury. Lipids. 26:1991;1310-1315.
11. Rubany G.M., Polokoff M.A. Endothelins Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology . Pharmacol Rev. 46:1994;325-415.
12. Khimenko P.L., Moore T.M., Taylor A.E. Blocked ETA receptors prevent ischemia and reperfusion injury in rat lungs. J Appl Physiol. 80:1996;203-207.
13. Gomez-Garre D., Guerra M., Gonzalez E., et al. Aggregation of human polymorphonuclear leukocytes by endothelin role of platelet-activating factor . Eur J Pharmacol. 224:1992;167-172.
14. Mizuta T., Kawaguchi A., Nakahara K., Kawashima Y. Simplified rat lung transplantation using a cuff technique. J Thorac Cardiovasc Surg. 97:1989;578-581.
15. Terashita Z., Takatani M., Nishikawa K. Pharmacological profile of TCV-309 - a potent PAF antagonist. J Lipid Mediat. 5:1992;183-185.
16. Goldblum S.E., Wu K.M., Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol. 59:1985;1978-1985.
17. Schmid R.A., Yamashita M., Ando K., Cooper J.D., Patterson G.A. Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts. Ann Thorac Surg. 61:1996;949-955.
18. Smith P.K., Krohn R.I., Hermanson G.T., et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 150:1985;768-785.
19. Zhao G., al-Mehdi A.B., Fisher A.B. Anoxia-reoxygenation versus ischemia in isolated rat lungs. Am J Physiol. 273:1997;L1112-L1117.
20. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 95:1979;351-358.
21. Bussolati B., Mariano F., Cignetti A., et al. Platelet-activating factor synthesized by IL-12-stimulated polymorphonuclear neutrophils and NK cells mediates chemotaxis. J Immunol. 161:1998;1493-1500.
22. Heller R., Bussolino F., Ghigo D., et al. Human endothelial cells are target for platelet-activating factor. II. Platelet-activating factor induces platelet-activating factor synthesis in human umbilical vein endothelial cells. J Immunol. 149:1992;3682-3688.
23. Noel P.E., Fletcher J.R., Thompson W.J. Rolipram and isoproterenol reverse platelet activating factor-induced increases in pulmonary microvascular permeability and vascular resistance. J Surg Res. 59:1995;159-164.
24. Uhlig S., Wollin L., Wendel A. Contributions of thromboxane and leukotrienes to PAF-induced impairment of lung function in the rat. J Appl Physiol. 77:1994;262-269.
25. Serizawa A., Nakamura S., Suzuki Baba S., Nakano M. Involvement of platelet-activating factor in cytokine production and neutrophil activation after hepatic ischemia-reperfusion. Hepatology. 23:1996;1656-1663.
26. Sirois M.G., de Lima W.T., de Brum Fernandes A.J., et al. Effect of PAF on rat lung vascular permeability Role of platelets and polymorphonuclear leucocytes . Br J Pharmacol. 111:1994;1111-1116.
27. Uhlig S., von B.A., Featherstone R.L., Wendel A. Pharmacologic characterization of endothelin receptor responses in the isolated perfused rat lung. Am J Respir Crit Care Med. 152:1995;1449-1460.
28. Aharinejad S., Schraufnagel D.E., Miksovsky A., Larson E.K., Marks S.C.J. Endothelin-1 focally constricts pulmonary veins in rats. J Thorac Cardiovasc Surg. 110:1995;148-156.
29. Shennib H., Serrick C., Saleh D., et al. Plasma endothelin-1 levels in human lung transplant recipients. J Cardiovasc Pharmacol. 26:(suppl 3):1995;S516-S518.
30. Filep J.G., Fournier A., Földes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung Involvement of ETA and ETB receptors . Br J Pharmacol. 115:1995;227-236.
31. Lopez-Farre A., Riesco A., Espinosa G., et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 88:1993;1166-1171.
32. Ishida K., Takeshige K., Minakami S. Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun. 173:1990;496-500.
33. Filep J.G., Sirois M.G., Rousseau A., Fournier A., Sirois P. Effects of endothelin-1 on vascular permeability in the conscious rat Interactions with platelet-activating factor . Br J Pharmacol. 104:1991;797-804.
34. Yamanaka N., Takaya Y., Oriyama T., et al. Hepatoprotective effect of a nonselective endothelin receptor antagonist (TAK-044) in the transplanted liver. J Surg Res. 70:1997;156-160.
35. Shennib H., Lee A.G., Kuang J.Q., et al. Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Am J Respir Crit Care Med. 157:1998;1975-1981.
36. Qayumi A.K., English J.E., Duncan S., et al. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1. J Heart Lung Transplant. 16:1997;946-955.
37. Corcoran P.C., Wang Y., Katz N.M., et al. Platelet activating factor antagonist enhances lung preservation. J Surg Res. 52:1992;615-620.
38. Corcoran P.C., Wang Y., Katz N.M., et al. Platelet activating factor antagonist enhances lung preservation in a canine model of single lung allotransplantation. J Thorac Cardiovasc Surg. 104:1992;66-72.
39. Watanabe T., Awane Y., Ikeda S., et al. Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 114:1995;949-954.
40. Masuda Y., Sugo T., Kikuchi T., et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl)carbonyl]-L-alanyl-L-alpha- aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors. J Pharmacol Exp Ther. 279:1996;675-685.
41. Terashita Z., Kawamura M., Takatani M., et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 260:1992;748-755.
42. Ikeda S., Awane Y., Kusumoto K., et al. A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats. J Pharmacol Exp Ther. 270:1994;728-733.